Press Release

October 31, 2026 BSE Limited National Stock Exchange of India Limited P. J. Towers, Exchange Plaza, Plot No. C/1, Dalal Street, G Block, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (E) Mumbai- 400 051 Scrip Code-540025 Trading Symbol-ADVENZYMES Subject: Press Release Ref: ISIN: INE837H01020 Dear Sir/Madam, Pursuant to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed is Press Release, titled "Quarterly Earnings Release” dated October 31, 2026. This is for your information and for public at large. Thanking you, Yours faithfully, For Advanced Enzyme Technologies Limited Sanjay Basantani Company Secretary and Head – Legal Encl.: As above FOR IMMEDIATE RELEASE QUARTERLY EARNINGS RELEASE Thane, India: Saturday, October 31, 2026 Advanced Enzyme Technologies Limited announces Financial Results for Second Quarter and Half Year ended September 2026 Advanced Enzyme Technologies Limited (Advanced Enzymes; NSE: ADVENZYMES; BSE: 540025), a leading specialty biotech company, with global leadership in the manufacturing of enzymes & probiotics, today announced their unaudited financial results for second quarter and half year ended September 2026. CONSOLIDATED QUARTERLY FINANCIAL HIGHLIGHTS: Q2 Q1 Q2 Change Change H1 H1 Change (Amount in INR Mn.) FY27 FY27 FY26 (Y-o-Y %) (Q-o-Q %) FY27 FY26 (%) Revenue 2,145 1,917 1,845 16% 12% 4,062 3,704 10% EBITDA 721 529 601 20% 36% 1,250 1,165 7% EBITDA Margin (%) 34% 28% 33% 31% 31% PAT 512 386 447 14% 33% 897 852 5% PAT Margin (%) 24% 20% 24% 22% 23% EPS 4.33 3.31 3.87 12% 30% 7.64 7.44 3% CONSOLIDATED FINANCIAL REVIEW (Y-o-Y basis): Revenue from Operations: Margin: Revenue from operations on consolidated basis EBITDA margin stands at 34%, PBT margin stands increased to ₹ 2,145 million in Q2 FY27 from ₹ at 32% and PAT margin stands at 24% during the 1,845 million in the Q2 FY26, a growth of 16%. quarter. Profit: Financial Costs: Consolidated EBITDA during Q2 FY27 stands at Financial costs stood at ₹ 12 million during Q2 ₹ 721 million as compared to ₹ 601 million during FY27 as against ₹ 7 million in Q2 FY26. Q2 FY26, increased by 20%. Depreciation and Amortization: Profit before tax stands at ₹ 688 million during Q2 Depreciation and Amortization charge for Q2 FY27 as against ₹ 595 million in Q2 FY26, FY27 stood at ₹ 109 million as compared to ₹ 101 increased by 15%. million in the same quarter previous year. Profit after tax grew by 14% and stands at ₹ 512 Earnings Per Share: million during Q2 FY27 as compared to ₹ 447 Earnings Per Share during Q2 FY27 stands at million during Q2 FY26. ₹ 4.33 as compared to ₹ 3.87 in Q2 FY26. www.advancedenzymes.com 1 OPERATIONAL PERFORMANCE REVIEW: Segmental Revenue: Human Nutrition Q2 Q2 Change (Amount in INR Mn.) FY27 FY26 (%) 17% Animal Nutrition Human Nutrition 1,285 1,212 6% Bio-Processing Animal Nutrition 265 193 37% 12% Specialized Manufacturing Bio-Processing 365 255 43% Specialized Manufacturing 231 185 25% The total revenue from operations grew by 16% on The Bio-Processing segment delivered a strong y-o-y basis and 12% on q-o-q basis. performance during the quarter, with revenue growing 43% y-o-y to ₹365 million in Q2 FY27, Revenue from the Human Nutrition segment compared with ₹255 million in Q2 FY26. Within the increased by 6% y-o-y to ₹1,285 million in Q2 FY27, segment, the Food business recorded robust compared with ₹1,212 million in Q2 FY26. This growth of 48% y-o-y, achieving revenue of ₹305 growth was primarily attributable to improved million in Q2 FY27. Meanwhile, the Non-Food sales in the Pharma/API business, Biocatalysis business registered growth of 21% y-o-y, with and Nutrition business. revenue reaching ₹60 million during the quarter. The Animal Nutrition segment reported a growth The Specialized Manufacturing segment of 37% on y-o-y basis to ₹265 million in Q2 FY27, contributed 11% to the Company's total revenue compared with ₹193 million in Q2 FY26. during the quarter, with revenue increasing by 25% y-o-y to ₹231 million. Geographical Revenue: 4% Domestic sales accounted for ₹ 1,110 million in 13% Q2 FY27 as compared to ₹ 887 million in Q2 India FY26, higher by 25%. 5% Americas The total revenue comprises of International Europe sales amounting to ₹ 1,035 million in Q2 FY27 as Asia (ex-India) compared to ₹ 958 million in Q2 FY26, an 27% Rest of the world increase of 8%. The revenue grew by 4% in Americas, 6% in Asia (ex-India) and 156% in the rest of the world while registered a de-growth of 10% in Europe. The domestic sales constituted about 52% of revenue from operations during Q2 FY27 as compared to 48% during Q2 FY26. International sales were 48% of revenue from operations during Q2 FY27 as compared to 52% during Q2 FY26. www.advancedenzymes.com 2 CONSOLIDATED FINANCIAL REVIEW (Q-o-Q basis): Revenue from Operations: ₹ 386 million during Q1 FY27. Revenue from operations on consolidated basis increased to ₹ 2,145 million in Q2 FY27 from Financial Costs: ₹ 1,917 million in Q1 FY27, a growth of 12%. Financial costs increased to ₹ 12 million during Q2 FY27 as compared to ₹ 6 million in Q1 FY27. Profit: Consolidated EBITDA during Q2 FY27 stands at Depreciation and Amortization: ₹ 721 million as compared to ₹ 529 million during Depreciation and Amortization charge for Q2 Q1 FY27, higher by 36%. FY27 is ₹ 109 million as compared to ₹ 99 million in the last quarter. Profit before tax stands at ₹ 688 million during Q2 FY27 as against ₹ 535 million in Q1 FY27, Earnings Per Share: increased by 28% Earnings Per Share during Q2 FY27 stands at ₹ 4.33 as compared to ₹ 3.31 in Q1 FY27. Profit after tax grew by 33% and stands at ₹ 512 million during Q2 FY27 as compared to OPERATIONAL PERFORMANCE REVIEW: Segmental Revenue: The Animal nutrition grew by 5% to ₹ 265 million in Q2 Q1 Change (Amount in INR Mn.) Q2 FY27 as against ₹ 252 million in Q1 FY27. FY27 FY27 (%) Human Nutrition 1,285 1,158 11% The Bio-Processing segment recorded a 19% q-o- q growth in revenue to ₹365 million in Q2 FY27, Animal Nutrition 265 252 5% compared with ₹306 million in Q1 FY27. Within the Bio-Processing 365 306 19% segment, the Food business recorded a 16% q-o- q increase in revenue to ₹305 million, while the Specialized Manufacturing 231 200 15% Non-Food business registered a 37% q-o-q growth to ₹60 million. The human nutrition segment reflected a growth 11% to ₹ 1,285 million in Q2 FY27 as compared to The Specialized manufacturing segment ₹ 1,158 million in Q1 FY27. registered a growth of 15% to ₹ 231 million in Q2 FY27 from ₹ 200 million in Q1 FY27. Geographical Revenue: Domestic sales accounted for ₹ 1,110 million in Q2 Revenue grew by 2% in the Americas, 12% in Asia FY27 as compared to ₹ 937 million in Q1 FY27, a (ex-India), and 103% in the Rest of the World, while growth of 18%. The domestic sales constituted Europe registered a decline of 21%. about 52% of revenue from operations during Q2 FY27 as compared to 49% during Q1 FY27. International sales were 48% of revenue from operations during Q2 FY27 as compared to 51% Total revenue comprises international sales of during Q1 FY27. ₹1,035 million in Q2 FY27, compared to ₹980 million in Q1 FY27, representing a growth of 6%. www.advancedenzymes.com 3 CONSOLIDATED HALF YEARLY FINANCIAL REVIEW (YTD basis): Revenue from Operations: Revenue from operations on consolidated basis Margin: increased to ₹ 4,062 million in the H1 FY27 from EBITDA margin stands at 31%, PBT margin stands ₹ 3,704 million in the H1 FY26, reported higher by at 30% and PAT margin stands at 22% during the 10%. H1 FY27. Profit: Financial Costs: Consolidated EBITDA during H1 FY27 stands at Financial costs stood at ₹ 18 million during H1 ₹ 1,250 million as compared to ₹ 1,165 million FY27 as against ₹ 15 million in H1 FY26. during H1 FY26, growth of 7%. Depreciation and Amortization: Profit before tax stands at ₹ 1,223 million during Depreciation and Amortization charge for the H1 H1 FY27 as against ₹ 1,144 mill [Showing first 8,000 characters — download PDF for full document]